Review



choline transporter 1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech choline transporter 1
    Choline Transporter 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter 1/product/Proteintech
    Average 93 stars, based on 3 article reviews
    choline transporter 1 - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    choline transporter 1  (Proteintech)
    93
    Proteintech choline transporter 1
    Choline Transporter 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter 1/product/Proteintech
    Average 93 stars, based on 1 article reviews
    choline transporter 1 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    choline transporter  (Proteintech)
    93
    Proteintech choline transporter
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter/product/Proteintech
    Average 93 stars, based on 1 article reviews
    choline transporter - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    choline transporter-like protein 1 pa5-90449 antibody  (Thermo Fisher)
    90
    Thermo Fisher choline transporter-like protein 1 pa5-90449 antibody
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter Like Protein 1 Pa5 90449 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter-like protein 1 pa5-90449 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    choline transporter-like protein 1 pa5-90449 antibody - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    mouse anti high affinity choline transporter 1  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse anti high affinity choline transporter 1
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Mouse Anti High Affinity Choline Transporter 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti high affinity choline transporter 1/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse anti high affinity choline transporter 1 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    anti-high affinity choline transporter 1 (cht-1)  (Millipore)
    90
    Millipore anti-high affinity choline transporter 1 (cht-1)
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Anti High Affinity Choline Transporter 1 (Cht 1), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-high affinity choline transporter 1 (cht-1)/product/Millipore
    Average 90 stars, based on 1 article reviews
    anti-high affinity choline transporter 1 (cht-1) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    anti-high affinity choline transporter 1 (cht-1  (Millipore)
    90
    Millipore anti-high affinity choline transporter 1 (cht-1
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Anti High Affinity Choline Transporter 1 (Cht 1, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-high affinity choline transporter 1 (cht-1/product/Millipore
    Average 90 stars, based on 1 article reviews
    anti-high affinity choline transporter 1 (cht-1 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    choline transporter-like protein-1 gene expression profiles  (Biotechnology Information)
    90
    Biotechnology Information choline transporter-like protein-1 gene expression profiles
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter Like Protein 1 Gene Expression Profiles, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter-like protein-1 gene expression profiles/product/Biotechnology Information
    Average 90 stars, based on 1 article reviews
    choline transporter-like protein-1 gene expression profiles - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline transporter-like protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.

    Journal: Journal of pharmaceutical analysis

    Article Title: Discovering metabolic vulnerability using spatially resolved metabolomics for antitumor small molecule-drug conjugates development as a precise cancer therapy strategy.

    doi: 10.1016/j.jpha.2023.02.010

    Figure Lengend Snippet: Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline transporter-like protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.

    Article Snippet: Antibodies were purchased from Invitrogen (Thermo Fisher Scientific): choline transporter-like protein 1 (CTL1, PA5-90449), carboxylesterase (CES, PA5-109518); and Proteintech (Wuhan, China): organic cation transporter 1 (OCT1, 24617-1-AP), OCT2 (13594-1-AP).

    Techniques: Staining, Mass Spectrometry, Western Blot, Expressing, Gene Expression, Standard Deviation